Clinical Trends for July 2017

Ryan Syrek

Disclosures

July 28, 2017

Clinical Trend of the Week (July 15-21): Ketamine

A new study that may lead to the development of safer alternatives for a psychoactive drug is responsible for this week's top search term. Results published in Nature found that ketamine blocks the N-methyl-D-aspartate receptor (NMDAR), allowing for an initial antidepressant effect. The study also found that the ketamine metabolite hydroxynorketamine (HNK) may extend the length of the antidepressant effect, which could help in the quest for safer alternatives. These findings are somewhat in conflict with another recent study, meaning further investigation is needed in order to provide a safe treatment for individuals with depression.

For more information on depression, read here.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....